– DJSI World Highlights the Most Sustainable Companies Around the World Based on Corporate Sustainability Assessment –
– Ranking Reflects Gilead’s Ongoing Commitment to Corporate Responsibility –
Washington, D.C. protest is one of three PROTESTS targeting Gilead that AHF has set for Thursday, December 1st, with the other two taking place in Miami and Oceanside, CA, all at local Gilead offices
Advocates target Gilead’s insatiable greed and its drug pricing and policies, including illegal restrictions the drug company places for certain pharmacies on access to 340B drug pricing for Gilead’s branded hepatitis C treatments
64 physicians comprise Cohort II, bringing the total to 116 participants in the program’s second year
– Gilead Will Provide up to $5 Million in Global Grant Funding to Immediately Support Public Education and Vaccine Hesitancy Communications, a Public Policy Response and a Global Outbreak Emergency Fund for Community Organizations in Regions with Active Monkeypox Outbreaks –
Gilead Protest, Wednesday, May 18th, 12:00 pm Foster City, CA
In March, Gilead imposed conditions illegally restricting access on 340B drug pricing to its branded hepatitis C treatments when covered entities use outside contract pharmacies. Gilead has the ignominious distinction of being the 15th manufacturer to place similar unlawful restrictions on certain 340B contract pharmacy programs
Gilead Protest, Thursday, May 5th, 12:00 pm Foster City, CA
In March, Gilead imposed conditions illegally restricting access on 340B drug pricing to its branded hepatitis C treatments when covered entities use outside contract pharmacies. Gilead has the ignominious distinction of being the 15th manufacturer to place similar unlawful restrictions on certain 340B contract pharmacy programs
– Funding Will Reach Under-Resourced Communities Most Impacted by the HIV Epidemic and COVID-19 Pandemic –
Gilead Protest, Wed., March 23, 11:00 a.m., Foster City, CA
Last week, Gilead imposed conditions illegally restricting access on 340B drug pricing to its branded hepatitis C treatments when covered entities use outside contract pharmacies. Gilead has the ignominious distinction of being the 15th manufacturer to place similar unlawful restrictions on certain 340B contract pharmacy programs